中国药物经济学2025，Vol.20Issue(3)：9-16,8.DOI:10.12010/j.issn.1673-5846.2025.03.002
阿得贝利单抗一线治疗广泛期小细胞肺癌的药物经济学评价
Pharmacoeconomic Evaluation of Adebrelimab in the First-Line Treatment of Patients with Extensive Small Cell Lung Cancer
胡钊 1刘永军1
作者信息
- 1. 中国药科大学国际医药商学院,南京 211198
- 折叠
摘要
Abstract
Objective To conduct an evaluation of the economics of combination of Adebrelimab and standard chemotherapy and chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer(ES-SCLC).Methods The study was carried out by constructing a three-state partition survival model.Taking our country's health care system as the research perspective,the research objects were patients with extensive-stage small cell lung cancer,and the model period was 21 days.The pharmacoeconomic evaluation of the two treatment regimens was conducted by cost-utility analysis,and the robustness of the results was verified by sensitivity analysis.Results For patients with ES-SCLC,the ICUR value of Adebrelimab combined with chemotherapy compared with first-line chemotherapy was 824842.22 yuan/QALY,which was more than three times the GDP per capita in 2023,which may not be economical.The results of sensitivity analysis were consistent with the basic analysis results,showing that the basic analysis results were relatively robust.The results of the contextual analysis showed that the adebenosumab combination chemotherapy regimen was cost-effective when a charitable gift program was conducted or when adebenosumab entered Medicare reimbursement.Conclusion Under the threshold of 3 times the GDP per capita in our country in 2023,for patients with ES-SCLC,Adebrelimab combined with chemotherapy may not be economical compared with first-line chemotherapy.关键词
阿得贝利单抗/程序性死亡受体配体1/广泛期小细胞肺癌/分区生存模型/药物经济学评价Key words
Adebrelimab/PD-L1/Extensive-stage small cell lung cancer/Partition survival model/Pharmacoeconomic evaluation分类
临床医学引用本文复制引用
胡钊,刘永军..阿得贝利单抗一线治疗广泛期小细胞肺癌的药物经济学评价[J].中国药物经济学,2025,20(3):9-16,8.
